Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS

Neurology

Volumn 82, Issue 1, 2014, Pages 41-48

  Ristori, Giovanni ^a   Romano, Silvia ^a   Cannoni, Stefania ^a   Visconti, Andrea ^a   Tinelli, Emanuele ^b   Mendozzi, Laura ^d   Cecconi, Pietro ^d   Lanzillo, Roberta ^e   Quarantelli, Mario ^f   Buttinelli, Carla ^a   Gasperini, Claudio ^c   Frontoni, Marco ^b   Coarelli, Giulia ^a   Caputo, Domenico ^d   Bresciamorra, Vincenzo ^e   Vanacore, Nicola ^g   Pozzilli, Carlo ^b   Salvetti, Marco ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^e CNR   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BETA1A INTERFERON; GADOLINIUM; PLACEBO;

ADULT; ARTICLE; BRAIN DAMAGE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYCOBACTERIUM BOVIS BCG; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT DURATION; YOUNG ADULT;

EID: 84892183623     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000438216.93319.ab     Document Type: Article

References (32)

1. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346:158-164. (Pubitemid 34438881)
2. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-288. (Pubitemid 40545039)
3. Tintorè M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-972. (Pubitemid 44454586)
4. Fismiku LK, Brex PA, Altman DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817. (Pubitemid 351294716)
5. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group. New Engl J Med 2000;343:898-904.
6. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582. (Pubitemid 32488815)
7. Kappos L, Freedman M, Polman CH, et al; for the BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397. (Pubitemid 47189673)
8. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (Pre-CISe study): a randomized, double-blind, placebo-controlled trial. Lancet 2009;374:1503-1511.
9. Kappos L, Freedman M, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-997.
10. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta1-a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-684. (Pubitemid 43739821)
11. Kinkel RP, Donchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the controlled high-risk Avonex multiple prevention study in ongoing neurological surveillance. Arch Neurol 2012;69:183-190.
12. Ristori G, Buzzi MG, Sabatini U, et al. Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology 1999;53:1588-1589. (Pubitemid 29491961)
13. Paolillo A, Buzzi MG, Giugni E, et al. The effect of Bacille Calmette-Guerin on the evolution of the new enhancing lesions to hypointense T1 lesions in relapsing-remitting MS. J Neurol 2003;250:247-248. (Pubitemid 36223109)
14. Kodama S, Kuhtreiber W, Fujimura S, Dale EA, Faustman D. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 2003;302:1223-1227. (Pubitemid 37421029)
15. Qin Hy, Chaturvedi P, Singh B. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int Immunol 2004;16:1723-1732. (Pubitemid 40003860)
16. Zuany-Amorim C, Sawicka E, Manlius C, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccaeinduced allergen-specific regulatory T-cells. Nat Med 2002; 8:625-629. (Pubitemid 34633442)
17. El-Zein M, Parent ME, Benedetti A, Rousseau MC. Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies. Int J Epidemiol 2010;39:469-486.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452. (Pubitemid 14237132)
19. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003;126:1782-1789. (Pubitemid 36917337)
20. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
21. Bach JF. Infections and autoimmune diseases. J Autoimmunity 2005;25(suppl):74-80.
22. Sewell DL, Reinke EK, Co DO, et al. Infection with mycobacterium bovis BCG diverts traffic of myelin oligodendroglial glycoprotein autoantigen-specific T cells away from the central nervous system and ameliorates experimental autoimmune encephalomyelitis. Clin Diagn Lab Immunol 2003;10:564-572. (Pubitemid 36890439)
23. Faustman D, Davis M. TNF receptor 2 pathways: drug target for autoimmune diseases. Nat Rev Drug Discov 2010;9:482-493.
24. Kahn DA, Archer DC, Gold DP, Kelly CJ. Adjuvant immunotherapy is dependent on inducible nitric oxide synthase. J Exp Med 2001;193:1261-1268.
25. Sakaguchi S. Control of immune responses by naturally arising CD41 regulatory T cells that express Toll-like receptors. J Exp Med 2003;197:397-401. (Pubitemid 36278596)
26. Weber MS, Benkhoucha M, Lehmann-Horn K, et al. Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One 2010;5:e16009.
27. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007;61:97-108. (Pubitemid 46363837)
28. Ristori G, Buttinelli C, Pozzilli C, Fieschi C, Salvetti M. Microbe exposure, innate immunity and autoimmunity. Immunol Today 1999;20:54.
29. Smith SG, Lalor MK, Gorak-Stolinska P, et al. Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunol 2010;11:35.
30. Kawara M. Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization. Clin Immunol 2008; 129:492-498.
31. Faustman DL, Wang L, Okubo Y, et al. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 2012;7:e41756.
32. Cruz A, Fraga AG, Fountain JJ, et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010;207:1609-1616.